Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer
Molecular Metastasis in Lymph Nodes is Associated With Survival of Patients With Stage I NSCLC
1 other identifier
observational
237
0 countries
N/A
Brief Summary
Analysis of driver gene variation in early stage non-small cell lung cancer
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2009
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2019
CompletedFirst Submitted
Initial submission to the registry
February 6, 2020
CompletedFirst Posted
Study publicly available on registry
February 12, 2020
CompletedFebruary 12, 2020
February 1, 2020
6.9 years
February 6, 2020
February 9, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Driver gene mutation frequency of early stage NSCLC
Observe the driver gene mutation frequency in regional lymph nodes of early stage non-small cell lung cancer
2019
Correlation of Clinicopathological characteristics and driver gene mutation in regional lymph nodes of early stage NSCLC
Analyze the correlation between driver gene mutation and clinicopathological features in regional lymph nodes of early stage NSCLC
2019
Correlation between driver gene mutation and survival prognosis in regional lymph nodes of early stage NSCLC
Observe the correlation between driver gene mutation and survival prognosis in regional lymph nodes of early stage NSCLC
2019
Study Arms (2)
Driver gene mutation-positive
Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation positive.
Driver gene mutation-negative
Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation negative.
Interventions
Eligibility Criteria
Histologically or cytologically proven diagnosis of early stage NSCLC
You may qualify if:
- Female or male, 18 years of age or older
- Histologically or cytologically proven diagnosis of early stage NSCLC
- The lesion was completely resected by radical surgery
- Able to get tumor tissue sample
- Complete information of clinicopathological , survival, recurrence and metastasis can be obtained through follow-up
You may not qualify if:
- Combine with other tumor type
- The investigator judges the situation that may affect the clinical search process and results
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Tian Y, Lai Q, Zheng Y, Ying L, Wang C, Jin J, Huang M, Wu Y, Li H, Zhang J, Su D. Oncogenic Alterations in Histologically Negative Lymph Nodes Are Associated with Prognosis of Patients with Stage I Lung Adenocarcinoma. Cancers (Basel). 2022 Feb 6;14(3):824. doi: 10.3390/cancers14030824.
PMID: 35159091DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director of pathology
Study Record Dates
First Submitted
February 6, 2020
First Posted
February 12, 2020
Study Start
January 1, 2009
Primary Completion
December 1, 2015
Study Completion
June 1, 2019
Last Updated
February 12, 2020
Record last verified: 2020-02
Data Sharing
- IPD Sharing
- Will not share